CTKBNasdaqLaboratory Analytical InstrumentsUS GAAP · USD

Cytek Biosciences, Inc.

Cytek Biosciences designs and sells flow cytometry instruments, reagents, software and service offerings used to analyze cells for research and clinical applications. Its portfolio centers on full spectrum flow cytometry systems such as Cytek Aurora and Northern Lights, alongside conventional flow and image-based products acquired through the Luminex FCI business.

Kysy yhtiöstä
Liikevaihto201milj. USD
+0,5 %v/v
Liikevoitto (EBIT)−40,4milj. USD
−96,8 %v/v
EBIT-marginaali−20,0%
−9,8 %-yks.v/v
Nettotulos−66,5milj. USD
−1 005,3 %v/v
Vapaa kassavirta−8,8milj. USD
−140,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2021–2025

−50050100150200250milj. USD2021: 128 milj. USD2021: EBIT 9,2 milj. USD20212022: 164 milj. USD2022: EBIT −1,8 milj. USD20222023: 193 milj. USD2023: EBIT −28 milj. USD20232024: 200 milj. USD2024: EBIT −21 milj. USD20242025: 201 milj. USD2025: EBIT −40 milj. USD2025201−40
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Cytek Biosciences, Inc.

Liiketoiminta

Osuus liikevaihdosta
Instruments70 %

Flow cytometry systems and related hardware sold for cell analysis and immunophenotyping.

Consumables and reagents15 %

Reagents, reagent kits, loaders and other recurring-use products tied to installed instruments.

Software and digital ecosystem5 %

Cytek Cloud, QbSure and other software tools that support panel design, acquisition and workflow management.

Services10 %

Post-warranty service contracts, installations, repairs and maintenance support.

Tuotteet

Raportoitu · osuus liikevaihdosta
71,6%28,4%FY2025100 %
  • Products71,6 %
  • Services28,4 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Cytek sells primarily to research and applied-life-science users that need high-parameter cell analysis, including academic and government institutions, CROs, pharmaceutical and biotechnology companies, and clinical laboratories. The company also serves entry-to-mid-range users through its Guava line and clinical research customers through products intended for disease detection, diagnosis support and treatment monitoring.

Academic and government institutions

Buy instruments, reagents and software for basic research, immunology and cell biology; important for installed base and publications.

Pharmaceutical and biotechnology companies

Use the platform for translational research, assay development and therapy monitoring, especially where high sensitivity matters.

CROs

Purchase systems to support outsourced research workflows that require reproducible cell analysis and client-facing throughput.

Clinical laboratories and clinical research users

Adopt clinical-research-capable systems for disease detection, diagnosis support and monitoring applications.

Entry-to-mid-range cytometry users

Buy Guava systems for lower-cost, easier-to-use cell counting and lower-plex immunophenotyping.

Strategia

Cytek is trying to turn its installed base into recurring revenue by linking instruments with consumables, services and software. It is also pushing clinical research applications and expanding internationally, while continuing to invest in R&D, commercial infrastructure and the Cytek Cloud ecosystem.

Integrated workflow solutionsLyhyt aikaväli

Bundling instruments with reagents, software and services increases customer stickiness and recurring revenue.

Clinical research expansionKeskipitkä aikaväli

Clinical use cases can broaden the addressable market and support higher-value applications.

Global commercializationLyhyt aikaväli

Broader sales coverage is needed to convert scientific validation into revenue growth across regions.

Product and software developmentKeskipitkä aikaväli

New instruments and digital tools help defend against larger competitors and support premium positioning.

Maantiede

Q1/2026

Cytek sells directly in North America, Europe, China and parts of Asia-Pacific, while also using distributors in parts of Europe, Latin America, the Middle East, Africa and Asia-Pacific. Manufacturing is spread across Fremont, Wuxi, Seattle and Singapore, which supports global supply but also creates exposure to trade controls, supplier concentration and cross-border logistics.

USA52 %
EMEA23 %
Asia Pacific17 %
Kina7,7 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Cytek operates in a crowded cell analysis market where larger competitors have greater scale, brand recognition and R&D resources. Its business is also exposed to supplier concentration, export controls affecting China, and funding pressure from academic and government customers, which can make revenue more volatile and harder to scale profitably.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Competitive pressure in flow cytometry1Supplier concentration2China export and regulatory exposure3Academic funding sensitivity4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Competitive pressure in flow cytometryVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The market includes large incumbents with deeper resources and established customer bases, which can limit pricing power and adoption.

    KohdistuuInstrumentsConsumablesSoftware
  2. Supplier concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Key components such as lasers and semiconductors come from limited or sole-source suppliers, creating supply and cost risk.

    Kohdistuu: Manufacturing and product availability

  3. China export and regulatory exposureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    New U.S. export controls may affect products, technology transfer, manufacturing and R&D tied to China.

    KohdistuuSalesManufacturingResearch
  4. Academic funding sensitivityVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    NIH indirect cost reimbursement changes can reduce purchasing capacity at academic and government customers.

    Kohdistuu: Academic and government demand

  5. Execution risk from limited operating historyVaikutus: Keskitaso

    The company has a relatively short commercial track record, making growth, margin and demand trends harder to predict.

    Kohdistuu: Commercial scaling and profitability

Kysy Clarifolta: Cytek Biosciences, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Instrument revenue is recognized at transfer of control, while services are recognized over time, creating mix-driven volatility.

Vaikutus: Quarterly revenue and gross margin can shift with shipment timing and service mix

Service contract accounting

Post-warranty contracts are recognized ratably, so deferred revenue and service backlog matter for forecasting.

Vaikutus: Affects recurring revenue visibility

Lease accounting

Operating leases for offices and facilities extend through 2029 and create fixed commitments.

Vaikutus: Impacts operating expenses and cash flow

Acquisition accounting

The Luminex FCI acquisition added Amnis and Guava assets that may carry intangible assets and goodwill.

Vaikutus: Potential impairment risk and amortization pressure

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Quanterix Corp

QTRX · Laboratory Analytical Instruments

Natera, Inc.

NTRA · Services-Medical Laboratories

CytomX Therapeutics, Inc.

CTMX · Pharmaceutical Preparations

HUTCHMED (China) Ltd

HCM · Pharmaceutical Preparations

Maravai LifeSciences Holdings, Inc

MRVI · Pharmaceutical Preparations

CytoMed Therapeutics Ltd

GDTC · Pharmaceutical Preparations

Päivitetty: 24.9.2026